Mechanisms of resistance to FLT3 inhibitors
SH Chu, D Small - Drug Resistance Updates, 2009 - Elsevier
The success of the small molecule tyrosine kinase receptor inhibitor (TKI) imatinib mesylate
(Gleevec) in the treatment of chronic myeloid leukemia (CML) constitutes an eminent
paradigm shift advocating the rational design of cancer therapeutics specifically targeting
the transformation events that drive tumorigenicity. In acute myeloid leukemias (AMLs), the
most frequent identified transforming events are activating mutations in the FLT3 receptor
tyrosine kinase that constitutively activate survival and proliferation pathways. FLT3 TKIs that …
(Gleevec) in the treatment of chronic myeloid leukemia (CML) constitutes an eminent
paradigm shift advocating the rational design of cancer therapeutics specifically targeting
the transformation events that drive tumorigenicity. In acute myeloid leukemias (AMLs), the
most frequent identified transforming events are activating mutations in the FLT3 receptor
tyrosine kinase that constitutively activate survival and proliferation pathways. FLT3 TKIs that …